Advancements in Ophthalmic Drug Formulations are Improving Treatment Effectiveness

Superficial punctate keratitis (SPK) treatment market was valued at $1,470 million in 2024 and is projected to reach $3,850 billion by 2035, growing at a CAGR of 9.2% from 2025 to 2035. Superficial Punctate Keratitis (SPK) treatment aims to relieve symptoms, heal the corneal surface, along with addressing root causes. The increasing advancements in ophthalmic drug formulations are considerably improving the effectiveness of Superficial Punctate Keratitis (SPK) treatment. The improvement enables better drug delivery, enhanced bioavailability, and longer retention time on the ocular surface. For instance,

Browse the full report description of “Superficial Punctate Keratitis Treatment Market Size, Share & Trends Analysis by Product Type (Drops, Ointments, and Others (Bandages)), By Route Of Administration (Oral and Topical), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/superficial-punctate-keratitis-treatment-market

• In September 2025, Sagent announced the launch of Travoprost Ophthalmic Solution. Travoprost Ophthalmic Solution assists in elevating intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also revealed that the company is expanding into the ophthalmic space to broaden its portfolio.

• In April 2025, Nordic Group’s subsidiary, Nordic Pharma, partnered with Harrow for the launch of Maxitrol. Maxitrol is an authorized generic containing neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension.

Key Players and Innovations

The key players in the superficial punctate keratitis treatment market include AbbVie (Allergan), Johnson & Johnson Vision, Bausch + Lomb, Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Alcon Vision LLC, Pfizer Inc., Merck KGaA, and Dompé US, Inc., among others. Such companies are at the forefront of innovation, focusing on the development of advanced ophthalmic formulations, enhancing drug delivery technologies, and exploring novel therapeutic approaches to improve patient outcomes and address the growing prevalence of Superficial Punctate Keratitis. For instance, in August 2024, the European Commission granted the first approval for a medicine to treat acanthamoeba keratitis, an ultra-rare corneal infection that can lead to blindness. Akantior (Polihexanide) is indicated for individuals from 12 years old in Europe. Akantior was developed by the company SIFI.

Market Coverage

• The market number available for – 2024-2035
• Base year- 2024
• Forecast period- 2025-2035
• Segment Covered-
  • By Product Type
  • By Route of Administration
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – AbbVie, Alcon Vision LLC, Bausch + Lomb Corp., Johnson & Johnson Vision, Santen Pharmaceutical Co., Ltd., and others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Superficial Punctate Keratitis Treatment Market Report Segment

By Product Type

• Drops
• Ointments
• Others (Bandages)

By Route Of Administration

• Oral
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Superficial Punctate Keratitis Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/superficial-punctate-keratitis-treatment-market